Single shot of radiation can save prostate cancer patients misery of weeks of treatment, study finds

High dose-rate brachytherapy – which delivers a surge of radiotherapy direct to the prostate in a single session – is safe and effective for men with low-risk cancer, researchers found.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Madam — This letter is a response to the recent overview on high dose rate (HDR) brachytherapy in high-risk localised disease in the prostate cancer special issue by Morton and Alrashidi [1].
Source: Clinical Oncology - Category: Radiology Authors: Tags: Letter Source Type: research
AbstractBackgroundThe specific association between PTEN deletion or ERG rearrangement and the recurrence of prostate cancer (PC) treated with radical prostatectomy (RP) or brachytherapy is still unelaborated. Therefore, we performed a comprehensive meta ‑analysis to understand the impact of these factors on cancer recurrence.MethodsA comprehensive literature search was performed in November 2018 based on PUBMED, EMBASE and Web of science database. Hazard ratio (HR) for biochemical recurrence free (BRF) which was defined as a PSA greater than or equal to 0.4  ng/mL after RP or another therapy for any detectable PSA a...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
To assess the correlation between postimplant dosimetric quantifiers and the genitourinary (GU) toxicity of low-dose rate brachytherapy for prostate cancer.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
ConclusionPre-clinical experiments demonstrated promising results for in-situ confirmation of lesion locations in prostates using Raman spectroscopy, both in phantoms and human ex-vivo prostate tissue, which is required for integration in HDR brachytherapy procedures.
Source: International Journal of Computer Assisted Radiology and Surgery - Category: Intensive Care Source Type: research
Men with Gleason grade Group (GG) 4 and 5 prostate cancer have high failure rates when treated by conventional therapy. We investigated the effect of higher radiation doses on freedom from biochemical failure (FBF) and prostate cancer mortality (cause-specific survival [CSS]) in men treated with a combination of permanent implant and external beam irradiation (EBRT).
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
High dose-rate (HDR) brachytherapy is commonly administered as a boost to external beam radiation therapy (EBRT). Our purpose was to compare toxicity with increasingly hypofractionated EBRT in combination with a single 15  Gy HDR boost for men with intermediate-risk prostate cancer.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Conclusions: This study highlights excellent outcomes for intermediate-risk prostate cancer patients, including unfavorable intermediate-risk cases, treated with BED ≥ 200 Gy radiotherapy using LDR brachytherapy. LDR alone with a BED of 200 Gy may be an optimal treatment for both favorable and unfavorable intermediate-risk prostate cancer patients, although a longer follow-up is mandatory to confirm the present findings. PMID: 32190064 [PubMed]
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
Conclusions: The excellent long-term results and low morbidity presented as well as many advantages of prostate brachytherapy over other treatments demonstrates that brachytherapy is an effective treatment for patients with transurethral resection and organ-confined prostate cancer. PMID: 32190063 [PubMed]
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
AbstractUrinary retention and hematuria owing to radiation-induced mucositis are occasional late adverse events in patients with prostate cancer. Moreover, radiation-induced secondary malignancies are late adverse events, although they are extremely rare. Herein, we describe a case of radiation-induced secondary malignancy of the prostate that was initially difficult to distinguish from radiation mucositis. A 74-year-old man with prostate cancer underwent brachytherapy and external beam radiotherapy 9 years ago. Twenty-eight months after irradiation, he presented with urinary retention and hematuria owing to radiation muco...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
ConclusionIn this prospectively analyzed subcohort of patients with AS and conventional staging within a randomized trial, the 2-year histological reclassification rates were higher than those previously reported. Active surveillance may not be based on conventional staging alone, and patients with grade group 2 cancers may be recommended for active surveillance in carefully controlled trials only.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Health | Prostate Cancer | Study